Mass spectrometry based protein biomarkers and drug target discovery and clinical diagnosis in Age-Related progressing neurodegenerative diseases

References

• Aikawa H, Hayashi M, Ryu S, Yamashita M, Ohtsuka N, Nishidate M, Fujiwara Y, Hamada A. 2016. Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. Sci Rep. 6:23749.
   PubMed Web of Science ®Google Scholar
• Alharbi RA. 2020. Proteomics approach and techniques in identification of reliable biomarkers for diseases. Saudi J Biol Sci. 27(3):968–974.
   PubMed Web of Science ®Google Scholar
• Baghel US, Singh A, Singh D, Sinha M. 2017. Application of mass spectroscopy in pharmaceutical and biomedical analysis. spectroscopic analyses - developments and applications. EramSharmin and Fahmina Zafar. IntechOpen. p. 105–121. https://doi.org/http://dx.doi.org/10.5772/intechopen.70655
   Google Scholar
• Barschke P, Oeckl P, Steinacker P, Al Shweiki MR, Weishaupt JH, Landwehrmeyer GB, Anderl-Straub S, Weydt P, Diehl-Schmid J, Danek A, et al.; the German FTLD consortium. 2020. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion, Journal of Neurology. J Neurol Neurosurg Psychiatry. 91(5):503–511.
   PubMed Web of Science ®Google Scholar
• Barschke P, Oeckl P, Steinacker P, Ludolph A, Otto M. 2017. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics. 14(9):769–777.
   PubMed Web of Science ®Google Scholar
• Bereman MS, Kirkwood KI, Sabaretnam T, Furlong S, Rowe DB, Guillemin GJ, Mellinger AL, Muddiman DC. 2020. Metabolite profiling reveals predictive biomarkers and the absence of β-methyl amino-l-alanine in plasma from individuals diagnosed with amyotrophic lateral sclerosis, (2020). J Proteome Res. 19(8):3276–3285.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee P, Öhrfelt A, Lashley T, Blennow K, Brinkmalm A, Zetterberg H. 2019. Mass spectrometric analysis of lewy body-enriched α-synuclein in parkinson's disease. J Proteome Res. 18(5):2109–2120.
   PubMed Web of Science ®Google Scholar
• Botas A, Campbell HM, Han X, Maletic-Savatic M. 2015. Metabolomics of neurodegenerative diseases. Int Rev Neurobiol. 122:53–80.
   PubMed Web of Science ®Google Scholar
• Buchberger AR, DeLaney K, Johnson J, Li L. 2018. Mass spectrometry imaging: a review of emerging advancements and future insights. Anal Chem. 90(1):240–265.
   PubMed Web of Science ®Google Scholar
• Carlyle BC, Trombetta BA, Arnold SE. 2018. Proteomic Approaches for the discovery of biofluid biomarkers of neurodegenerative dementias. Proteomes. 6(3):32.
   PubMed Web of Science ®Google Scholar
• Chandramouli K, Qian PY. 2009. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics. 2009:239204.
   PubMedGoogle Scholar
• Chapman JD, Goodlett DR, Masselon CD. 2014. Multiplexed and data-independent tandem mass spectrometry for global proteome profiling. Mass Spectrom Rev. 33(6):452–470.
   PubMed Web of Science ®Google Scholar
• Chen K, Baluya D, Tosun M, Li F, Savatic MM. 2019. Imaging mass spectrometry: a new tool to assess molecular underpinnings of neurodegeneration. Metabolites. 9(7):135.
   PubMed Web of Science ®Google Scholar
• Chughtai K, Heeren R,MA. 2010. Mass Spectrometric Imaging for biomedical tissue analysis. Chem Rev. 110(5):3237–3277.
   PubMed Web of Science ®Google Scholar
• Cilento EM, Jin L, Stewart T, Shi M, Sheng L, Zhang J. 2019. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. J Neurochem. 151(4):397–416.
   PubMed Web of Science ®Google Scholar
• Comes AL, Papiol S, Mueller T, Geyer PE, Mann M, Schulze TG. 2018. Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future. Transl Psychiatry. 8(1):160.
   PubMed Web of Science ®Google Scholar
• Conrads T,P, Hood BL, Veenstra TD. 2006. Sampling and analytical strategies for biomarker discovery using mass spectrometry. Biotechniques. 40(6):799–805.
   PubMed Web of Science ®Google Scholar
• Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. 2016. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics. 13:1.
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron. 39(6):889–909.
   PubMed Web of Science ®Google Scholar
• Dolci A, Panteghini M. 2006. The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin Chim Acta. 369(2):179–187.
   PubMed Web of Science ®Google Scholar
• Foster LA, Salajegheh MK. 2019. Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med. 132(1):32–37.
   PubMed Web of Science ®Google Scholar
• Füzéry AK, Levin J, Chan MM, Chan DW. 2013. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 10(1):13.
   PubMed Web of Science ®Google Scholar
• Hawkridge A,M, Muddiman D,C. 2009. Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. Annu Rev Anal Chem. 2:265–277.
   PubMed Web of Science ®Google Scholar
• Hebert LE, Weuve J, Scherr PA, Evans DA. 2013. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 80(19):1778–1783.
   PubMed Web of Science ®Google Scholar
• Hedl TJ, Gil RS, Cheng F, Rayner SL, Davidson JM, Luca AD, Villalva MD, Ecroyd H, Walker AK, Lee A. 2019. Proteomics approaches for biomarker and drug target discovery in ALS and FTD. Front Neurosci. 13:548.
   PubMed Web of Science ®Google Scholar
• Henry KD, Williams ER, Wang BH, McLafferty FW, Shabanowitz J, Hunt DF. 1989. Fourier-transform mass spectrometry of large molecules by electrospray ionization. Proc Natl Acad Sci USA. 86(23):9075–9078.
   PubMed Web of Science ®Google Scholar
• Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, Hurst C, Glass JD, Factor SA, Johnson ECB, et. al. 2020. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease. Sci Adv. 6(43):eaaz9360.
   PubMed Web of Science ®Google Scholar
• Hirtz C, Vialaret J, Nouadje G, Schraen S, Benlian P, Mary S, et al. 2016. Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. Clin Chim Acta. 454:3–8.
   Web of Science ®Google Scholar
• Iridoy M, Zubiri I, Zelaya M, Martinez L, Ausín K, Lachen-Montes M, Santamaría E, Fernandez-Irigoyen J, Jericó I. 2018. Neuroanatomical quantitative proteomics reveals common pathogenic biological routes between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). IJMS. 20(1):4.
   Web of Science ®Google Scholar
• Joilin G, Gray E, Thompson AG, Bobeva Y, Talbot K, Weishaupt J, Ludolph A, Malaspina A, Leigh PN, Newbury SF, et al. 2020. Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis. Brain Commun. 2(1):fcaa053.
   PubMedGoogle Scholar
• Joilin G, Leigh PN, Newbury SF, Hafezparast M. 2019. An overview of microRNAs as biomarkers of ALS. Front Neurol. 10:186.
   PubMed Web of Science ®Google Scholar
• Jylha A, et al. 2018. Comparison of iTRAQ and SWATH in a clinical study with multiple time points. Clin. Proteomics. 15:24.
   PubMed Web of Science ®Google Scholar
• Kelleher NL. 2004. Top-down proteomics. Anal Chem. 76:197–203A.
   PubMed Web of Science ®Google Scholar
• Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, Strittmatter SM. 2017. Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related Phenotypes in Progranulin-Deficient Mice. Neuron. 95(2):281–296.e6.
   PubMed Web of Science ®Google Scholar
• Krach F, Batra R, Wheeler EC, Vu AQ, Wang R, Hutt K, Rabin SJ, Baughn MW, Libby RT, Diaz-Garcia S, et al. 2018. Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol. 136(3):405–423.
   PubMed Web of Science ®Google Scholar
• Laferrière F, Maniecka Z, Pérez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock E-M, Wagner U, Afroz T, Boersema PJ, Barmettler G, et al. 2019. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 22(1):65–77.
   PubMed Web of Science ®Google Scholar
• Leoni E, Bremang M, Mitra V, Zubiri I, Jung S, Lu C-H, Adiutori R, Lombardi V, Russell C, Koncarevic S, et al. 2019. Combined tissue-fluid proteomics to unravel phenotypic variability in amyotrophic lateral sclerosis. Sci Rep. 9(1):4478.
   PubMed Web of Science ®Google Scholar
• Li D, Chan DW. 2014. Proteomic cancer biomarkers from discovery to approval: it's worth the effort. Expert Rev Proteomics. 11(2):135–136.
   PubMed Web of Science ®Google Scholar
• Li KW, Ganz AB, Smit AB. 2019. Proteomics of neurodegenerative diseases: analysis of human post-mortem brain. J Neurochem. 151(4):435–445.
   PubMed Web of Science ®Google Scholar
• Loo JA, Edmonds CG, Smith RD. 1990. Primary sequence information from intact proteins by electrospray ionization tandem mass spectrometry. Science. 248(4952):201–204.
   PubMed Web of Science ®Google Scholar
• Loos G, Schepdael AV, Cabooter D. 2016. Quantitative mass spectrometry methods for pharmaceutical analysis. Phil Trans R Soc A. 374(2079):20150366.
   Web of Science ®Google Scholar
• Ludwig C, Gillet L, Rosenberger G, Amon S, Collins BC, Aebersold R. 2018. Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial. Mol Syst Biol. 14(8):e8126.
   PubMed Web of Science ®Google Scholar
• Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, et al.; Parkinson’s Foundation P4 Group. 2018. Prevalence of parkinson's disease across North America. NPJ Parkinsons Dis. 4:21.
   PubMed Web of Science ®Google Scholar
• Matamala JM, Arias-Carrasco R, Sanchez C, Uhrig M, Bargsted L, Matus S, Maracaja-Coutinho V, Abarzua S, van Zundert B, Verdugo R, et al. 2018. Genome-wide circulating microRNA expression profiling reveals potential biomarkers for amyotrophic lateral sclerosis. Neurobiol Aging. 64:123–138.
   PubMed Web of Science ®Google Scholar
• Meyer JG, Schilling B. 2017. Clinical applications of quantitative proteomics using targeted and untargeted data-independent acquisition techniques. Expert Rev Proteomics. 14(5):419–429.
   PubMed Web of Science ®Google Scholar
• Muddiman DC. 2006. "Lewis and Clark" proteomics. J Proteome Res. 5(2):221–222.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li Q-X, Martins R, Rowe C, et al. 2018. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature. 554(7691):249–254.
   PubMed Web of Science ®Google Scholar
• O'Bryant SE, Edwards M, Zhang F, Johnson LA, Hall J, Kuras Y, Scherzer CR. 2019. Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. Alzheimers Dement (Amst). 11:374–382.
   PubMedGoogle Scholar
• Oeckl P, Otto MA. 2019. A review on MS-based blood biomarkers for alzheimer's disease. Neurol Ther. 8(Suppl 2):113–127.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. 2020. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 139(1):119–134.
   PubMed Web of Science ®Google Scholar
• Olney NT, Spina S, Miller BL. 2017. Frontotemporal dementia. Neurol Clin. 35(2):339–374.
   PubMed Web of Science ®Google Scholar
• Park SA, Jung JM, Park JS, et al. 2020. SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer’s disease. SciRep. 10:7423.
   Google Scholar
• Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. 2019. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. 18(6):573–586.
   PubMed Web of Science ®Google Scholar
• Patel S, Ling J, Kim SJ, Schey KL, Rose K, Kuchtey RW. 2016. Proteomic analysis of macular fluid associated with advanced glaucomatous excavation. JAMA Ophthalmol. 134(1):108–110.
   PubMed Web of Science ®Google Scholar
• Portelius E, Brinkmalm G, Pannee J, Zetterberg H, Blennow K, Dahlén R, Brinkmalm A, Gobom J. 2017. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. Expert Rev Proteomics. 14(11):1007–1020.
   PubMed Web of Science ®Google Scholar
• Richard JA, Goodwin; Takats Z, Bunch JA. 2020. Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery. SLAS Discov. 25(9):963–976.
   PubMed Web of Science ®Google Scholar
• Rotunno MS, Lane M, Zhang W, Wolf P, Oliva P, Viel C, Wills A-M, Alcalay RN, Scherzer CR, Shihabuddin LS, et al. 2020. Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease. Sci Rep. 10(1):2479.
   PubMed Web of Science ®Google Scholar
• Sabino F, Hermes O, Auf Dem Keller U. 2017. Body Fluid Degradomics and Characterization of Basic N-Terminome. Methods Enzymol. 585:177–199.
   PubMed Web of Science ®Google Scholar
• Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, et al. 2019. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 93(17):e1647–e1659.
   PubMed Web of Science ®Google Scholar
• Schulz S, Michael Becker M, Groseclose R, Schadt S, Hopf C. 2019. Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development. Curr Opin Biotechnol. 55:51–59.
   PubMed Web of Science ®Google Scholar
• Shao Y, Le W. 2019. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. Mol Neurodegener. 14(1):3.
   PubMed Web of Science ®Google Scholar
• Swindell WR, Kruse CPS, List EO, Berryman DE, Kopchick JJ. 2019. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia. J Transl Med. 17(1):170.
   PubMed Web of Science ®Google Scholar
• Tholey A, Becker A. 2017. Top-down proteomics for the analysis of proteolytic events - Methods, applications and perspectives. Biochim Biophys Acta Mol Cell Res. 1864(11 Pt B):2191–2199.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, Thézénas M-L, Charles PD, Evetts S, Hu MT, Talbot K, Fischer R, Kessler BM, Turner MR, et al. 2018. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 83(2):258–268.
   PubMed Web of Science ®Google Scholar
• Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, Mcgrath M, Manfredi G, Maragakis N, Miller RG, Pullman SL, et al. 2013. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 14(Sup1):19–32.
   PubMed Web of Science ®Google Scholar
• Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, Gearing M, Glass JD, Seyfried NT. 2018. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 10(1):48–62.
   PubMed Web of Science ®Google Scholar
• Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJP, Wilkinson ID, Jenkins TM, Shaw PJ. 2019. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 10:291.
   PubMed Web of Science ®Google Scholar
• Washburn MP, Wolters D, Yates JR. 2001. 3rd Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol. 19(3):242–247.
   PubMed Web of Science ®Google Scholar
• Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M. 1996. Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature. 379(6564):466–469.
   PubMed Web of Science ®Google Scholar
• Wimo A, Jönsson L, Bond J, Prince M, Winblad B, Alzheimer Disease International 2013. The worldwide economic impact of dementia 2010. Alzheimers Dement. 9(1):1–11.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Cai A, Greenslade JE, Higgins NR, Fan C, Le NTT, Tatman M, Whiteley AM, Prado MA, Dieriks BV, et al. 2020. ALS/FTD mutations in UBQLN2 impede autophagy by reducing autophagosome acidification through loss of function. Proc Natl Acad Sci USA. 117(26):15230–15241.
   PubMed Web of Science ®Google Scholar
• Yoon S, Lee TG. 2018. Biological tissue sample preparation for time-of-flight secondary ion mass spectrometry (ToF-SIMS) imaging. Nano Converg. 5(1):24.
   PubMed Web of Science ®Google Scholar
• Yu F, Qiu F, Meza J. 2016. 12 – design and statistical analysis of mass-spectrometry-based quantitative proteomics data. In: Ciborowski P, Silberring J, editors. Proteomic profiling and analytical chemistry 2nd edn. Boston, MA: Elsevier, p. 211–237.
   Google Scholar
• Zhang W, Czernik AJ, Yungwirth T, Aebersold R, Chait BT. 1994. Matrix-assisted laser desorption mass spectrometric peptide mapping of proteins separated by two-dimensional gel electrophoresis: determination of phosphorylation in synapsin. I. Protein Sci. 3(4):677–686.
   PubMed Web of Science ®Google Scholar
• Zhou M, Haque RU, Dammer EB, et al. 2020. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease. ClinProteom 17:19.
   Google Scholar
• Zhou W, Petricoin EF, Longo C. 2017. Mass spectrometry-based biomarker discovery. Methods Mol Biol. 1606:297–311.
   PubMedGoogle Scholar